New drug duo aims to outsmart stomach cancer

NCT ID NCT06346197

Recruiting now Disease control Sponsor: Centre Leon Berard Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether a combination of two immunotherapy drugs (botensilimab and balstilimab) can help people with advanced stomach cancer live longer compared to standard treatment. The study includes 132 adults whose tumors have a specific genetic marker (MSI-H/dMMR). Participants will receive either the new drug combo or standard chemo plus another immunotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: botensilimab and balstilimab (immunotherapy drugs)
What this could lead to: If successful, this could offer a new treatment option for people with advanced stomach cancer that has specific genetic features.
What could go wrong: This is an early-stage Phase 3 trial with only 132 participants, so results may not apply to everyone. Immunotherapy can cause serious side effects like inflammation of organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer gastric cancer gastric neoplasm metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER GASTRIC CANCER METASTATIC CANCER MSI-H

Contacts and locations

Locations

CHU de Brest
RECRUITING

Brest, 29000, France
CHU de Clermont-Ferrand
RECRUITING

Clermont-Ferrand, 63000, France
CHU de Poitiers
RECRUITING

Poitiers, 86000, France
Centre Léon Bérard
RECRUITING

Lyon, 69008, France
Hôpital Privé Jean Mermoz
RECRUITING

Lyon, 69008, France
Institut Mutualiste Montsouris
RECRUITING

Paris, 75000, France
Institut Paoli Calmettes
RECRUITING

Marseille, 13000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.